Health & Biotech
Check out the latest Biotech news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts.
Health & Biotech
Scott Power: ‘Skip in our step’ as ASX health stocks shrug off losing streak
Health & Biotech
These ASX companies are stepping up to tackle traumatic brain injury head-on
Health & Biotech
How shifting to big pharma is paying off for Clever Culture Systems
Health & Biotech
Health Check: Join in the Coris as Nanosonics wins key FDA approval
StockTake
StockTake: AdAlta subsidiary AdCella secures funding boost
Health & Biotech
Health Check: Emvision’s stroke detector takes to the skies
Health & Biotech
The ASX pharmas playing the long game, with commercialisation the prize
Health & Biotech
Biocurious: FDA approval remains the Holy Grail for ASX life science stocks
Health & Biotech
Health Check: Fantastico! Telix wins Brazilian assent for prostate cancer imaging agent
Health & Biotech
Dr Boreham’s Crucible: This rare blood disease tackler aims to hit investors with its best shot
Health & Biotech
Health Check: These biotechs are awaiting key announcements on St Patrick’s Day
Health & Biotech
Scott Power: ASX health stocks feel force of market volatility
Health & Biotech
The ASX players bringing new hope to IPF sufferers
Health & Biotech
Health Check: All hail the hard-working bodily ‘spuds’ – it’s World Kidney Day
Health & Biotech
Health Kick Podcast: Imagion’s cancer imaging alternative
Health & Biotech
Health Check: Star biotech stocks are going cheap – or cheaper than they were
Health & Biotech
Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial
StockTake
StockTake: Singular Health cashes cornerstone stateside investment
Health & Biotech
Health Check: Poly oh no! Polynovo shares resume slide as CEO goes
Health & Biotech
Scott Power: ASX health sector falls as market faces gathering storm clouds
Health & Biotech
“Accelerate Action” to boost women’s leadership in Aussie healthcare sector
Health & Biotech
Health Check: More healthcare ‘reverse ferrets’ from Trump’s razor gang
Health & Biotech
Health Check: Telix ‘mini me’ Clarity moves to next phase of prostate cancer therapy trial
Biocurious: Sometimes an effective therapy lies not just with the drug, but how it is delivered
Health & Biotech
Health Check: Half-price sale as brokers ring the bell on Neuren shares
Health & Biotech
Dr Boreham’s Crucible: This MSA-tackling biotech strives to be ‘different’
Health & Biotech
Health Check: More biotechs change their names, but will they smell just as sweet?
Health & Biotech
Major Singaporean and Hong Kong investors bet on ASX healthcare’s upside
Experts
Criterion: Rollercoaster price movements are now part of the profit-reporting landscape
Health & Biotech
Scott Power: ASX healthcare stocks fall in ‘worst reporting season for a long time’
Health & Biotech
ReNerve revenue shoots up 167pc in first half year result since IPO
Health & Biotech
ReNerve inks Mexican deal for nerve repair product NervAlign
Health & Biotech
Health Check: You’re rehired! The Trump administration’s FDA staffing ‘fiasco’ puts sector in choppy, unchartered waters
Health & Biotech
Health Check: What’s up, Doc? Not much – post Covid patients are still avoiding GP visits
Long Shortz
Long Shortz with Imagion Biosystems: Moving milestones on next phase cancer detection
Health & Biotech
Biocurious: With Mayne Pharmaceuticals under takeover offer, who’s next?
Health & Biotech
Health Check: More, please! When record results are not good enough for expectant investors
Health & Biotech
Bargain Barrel: Four ASX cancer-fighting stocks with market caps under $35 million
Health & Biotech
Dr Boreham’s Crucible: This hearing-aid stock is well tuned in to an evolving, competitive field
Health & Biotech
Health Check: After an ‘extraordinary’ year, analysts reckon Telix has a lot more tiger in the tank
Health & Biotech
Scott Power: ASX health stocks up in mixed earnings season, Mayne surges on $672 million US buyout
Health & Biotech
Buddying up: How small ASX healthcare stocks are teaming with giants for growth
Health & Biotech
Health Check: It’s show-and-tell time for three of our home-grown heroes
Health & Biotech
Imagion to start production of MagSense imaging agent for phase II breast cancer trial
Health & Biotech
Health Check: EBOS Group’s earnings surge – or plunge – but bottom line is, pharmacies are in rude health
Health & Biotech
Middle East healthcare expansion opens doors for ASX stocks
Health & Biotech
Biocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapy
Load More